Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Key Movement
    • GSK appoints scientist...

    GSK appoints scientist Barron as new Research and Development head

    Written by Ruby Khatun Khatun Published On 2017-11-10T09:47:25+05:30  |  Updated On 18 Aug 2021 3:02 PM IST

    LONDON: GlaxoSmithKline (GSK) has poached veteran drug industry scientist Hal Barron from Alphabet-funded Calico to be its research head as new Chief Executive Emma Walmsley steps up her drive to improve productivity.


    Barron, who worked for Roche for many years before joining the new Google venture set up to tackle age-related health issues, will replace Patrick Vallance, who is taking up the post of chief scientific adviser to the British government.


    GSK has lagged behind rivals in recent years in producing multibillion-dollar blockbuster drugs. It has also suffered a number of high-profile clinical trial failures on Vallance's watch, undermining faith in its R&D skills.


    Walmsley said the appointment of Barron as president of R&D and a board member from Jan. 1 was a "very significant" move for Britain's biggest drugmaker.


    "This underscores the absolute, unequivocal prioritization I'm placing on improving our performance in our biggest business, which is pharma," she told Reuters on Wednesday. "Pharma R&D and the pipeline is at the heart of that."


    GSK shares ended 1.5 percent higher in a broadly flat market.


    Vallance's departure had been expected after a source familiar with the matter said last week he was quitting for the top British science post.


    His planned exit, at the end of March 2018, comes after Walmsley said in July she would narrow the focus of GSK's drug research by ditching more than 30 drug projects.


    GSK will in future allocate 80 percent of its R&D budget to respiratory and HIV/infectious diseases, along with two other potential areas of oncology and immuno-inflammation.


    CANCER FOCUS?


    The appointment of Barron will stoke speculation that cancer may soon be confirmed as a third official therapy focus, given his role in overseeing a range of blockbuster cancer drugs at Roche, including Avastin, Tarceva, and Perjeta.


    Although GSK sold its marketed cancer drugs to Novartis in 2015, it continues to invest in early-stage research and has recently made advances with a promising blood cancer drug.


    Walmsley said it would be up to Barron to decide where to invest once he joined the company in the new year, but she added his experience in oncology and in specialty therapy areas was "highly exciting".


    Significantly, Barron will remain based in San Francisco, where GSK will have a new office focused on deal-making opportunities in drug research.


    Barron will be paid a base salary of $1.7 million, with a bonus of $1.7 million and an expected $4.25 million in long-term incentive plan stock awards.


    Walmsley's plans for overhauling GSK have yet to fully convince investors, many of whom worry the dividend could be at risk if she twins a revamp of pharma with a big acquisition in consumer healthcare.


    She declined to comment any further on the dividend or her potential interest in Pfizer's consumer health division, beyond noting the U.S. company had yet to make a definitive decision on selling the unit.


    Barron is Walmsley's third key appointment, following her hiring of Luke Miels from AstraZeneca as head of pharmaceuticals and former Wal-Mart Stores executive Karenann Terrell as chief digital and technology officer.


    Barron and Miels both have experience working together at Roche and Walmsley said their partnership would help forge closer ties between commercial operations and drug R&D.


    (Reporting by Ben Hirschler; Editing by Edmund Blair and Mark Potter)

    BarronCalicoClinical TrialEmma WalmsleyGlaxoSmithKlineGSKHal Barronhealth issuesHIVinfectious diseasesPatrick Vallancepharma newsresearch and developmentresearch headRoche veteranscientists
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok